Tycel Phillips
Associate Professor
City of Hope · Duarte, United States
Lymphoma specialist at City of Hope focused on novel therapeutic approaches for MCL including cellular therapies and targeted agents.
Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025.
Cancer · Apr 15, 2026
Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma.
Blood advances · Mar 10, 2026
Copanlisib in combination with venetoclax in patients with relapsed/refractory mantle cell lymphoma.
Leukemia & lymphoma · Oct 31, 2025
Outpatient Brexucabtagene Autoleucel in B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma.
American journal of hematology · Oct 1, 2025
Perspectives on Current Challenges and Emerging Approaches for Lymphoma Management From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.
Clinical lymphoma, myeloma & leukemia · Jun 1, 2025
SOHO State of the Art Updates and Next Questions | The Current State of CAR T-Cell Therapy and Bispecific Antibodies in Mantle Cell Lymphoma.
Clinical lymphoma, myeloma & leukemia · May 1, 2025
A chemotherapy-free regimen of acalabrutinib, umbralisib and ublituximab achieved high response rates and undetectable minimal residual disease in patients with untreated mantle cell lymphoma.
British journal of haematology · May 1, 2025
Reply to: Glofitamab for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Apr 20, 2025
The Current State of Bispecific Antibodies and T-Cell Directed Therapy in NHL.
Cancers · Mar 31, 2025
Challenges of treating mantle cell lymphoma in older adults.
Leukemia & lymphoma · Mar 1, 2025
Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naïve or relapsed/refractory mantle cell lymphoma: phase Ib trial.
Haematologica · Mar 1, 2025
Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Jan 20, 2025
Nodal T-Cell Lymphoma Transdifferentiated from Mantle Cell Lymphoma with Epstein-Barr Virus Infection.
Pathobiology : journal of immunopathology, molecular and cellular biology · Jan 1, 2025
Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis.
Blood advances · Sep 10, 2024
Taking a BiTE out of Lymphoma: Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma.
Cancers · Apr 28, 2024
Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study.
Blood advances · Mar 12, 2024